ICD-10-PCS › 3
ICD-10-PCS codes starting with 3
1,516 codes, page 14 of 16. Every code ever valid for billing is listed, including those now retired.
| Code | Description | Status |
|---|---|---|
| 3E0Q3HZ | Introduction of Radioactive Substance into Cranial Cavity and Brain, Percutaneous Approach | Valid |
| 3E0Q3KZ | Introduction of Other Diagnostic Substance into Cranial Cavity and Brain, Percutaneous Approach | Valid |
| 3E0Q3NZ | Introduction of Analgesics, Hypnotics, Sedatives into Cranial Cavity and Brain, Percutaneous Approach | Valid |
| 3E0Q3SF | Introduction of Other Gas into Cranial Cavity and Brain, Percutaneous Approach | Valid |
| 3E0Q3TZ | Introduction of Destructive Agent into Cranial Cavity and Brain, Percutaneous Approach | Valid |
| 3E0Q704 | Introduction of Liquid Brachytherapy Radioisotope into Cranial Cavity and Brain, Via Natural or Artificial Opening | Valid |
| 3E0Q705 | Introduction of Other Antineoplastic into Cranial Cavity and Brain, Via Natural or Artificial Opening | Valid |
| 3E0Q70M | Introduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Via Natural or Artificial Opening | Valid |
| 3E0Q7SF | Introduction of Other Gas into Cranial Cavity and Brain, Via Natural or Artificial Opening | Valid |
| 3E0R0AZ | Introduction of Embryonic Stem Cells into Spinal Canal, Open Approach | Valid |
| 3E0R0E0 | Introduction of Autologous Somatic Stem Cells into Spinal Canal, Open Approach | Valid |
| 3E0R0E1 | Introduction of Nonautologous Somatic Stem Cells into Spinal Canal, Open Approach | Valid |
| 3E0R302 | Introduction of High-dose Interleukin-2 into Spinal Canal, Percutaneous Approach | Valid |
| 3E0R303 | Introduction of Low-dose Interleukin-2 into Spinal Canal, Percutaneous Approach | Valid |
| 3E0R304 | Introduction of Liquid Brachytherapy Radioisotope into Spinal Canal, Percutaneous Approach | Valid |
| 3E0R305 | Introduction of Other Antineoplastic into Spinal Canal, Percutaneous Approach | Valid |
| 3E0R30M | Introduction of Antineoplastic, Monoclonal Antibody, into Spinal Canal, Percutaneous Approach | Valid |
| 3E0R328 | Introduction of Oxazolidinones into Spinal Canal, Percutaneous Approach | Valid |
| 3E0R329 | Introduction of Other Anti-infective into Spinal Canal, Percutaneous Approach | Valid |
| 3E0R33Z | Introduction of Anti-inflammatory into Spinal Canal, Percutaneous Approach | Valid |
| 3E0R36Z | Introduction of Nutritional Substance into Spinal Canal, Percutaneous Approach | Valid |
| 3E0R37Z | Introduction of Electrolytic and Water Balance Substance into Spinal Canal, Percutaneous Approach | Valid |
| 3E0R3AZ | Introduction of Embryonic Stem Cells into Spinal Canal, Percutaneous Approach | Valid |
| 3E0R3BZ | Introduction of Anesthetic Agent into Spinal Canal, Percutaneous Approach | Valid |
| 3E0R3CZ | Introduction of Regional Anesthetic into Spinal Canal, Percutaneous Approach through FY2017 | Retired |
| 3E0R3E0 | Introduction of Autologous Somatic Stem Cells into Spinal Canal, Percutaneous Approach | Valid |
| 3E0R3E1 | Introduction of Nonautologous Somatic Stem Cells into Spinal Canal, Percutaneous Approach | Valid |
| 3E0R3GC | Introduction of Other Therapeutic Substance into Spinal Canal, Percutaneous Approach | Valid |
| 3E0R3HZ | Introduction of Radioactive Substance into Spinal Canal, Percutaneous Approach | Valid |
| 3E0R3KZ | Introduction of Other Diagnostic Substance into Spinal Canal, Percutaneous Approach | Valid |
| 3E0R3NZ | Introduction of Analgesics, Hypnotics, Sedatives into Spinal Canal, Percutaneous Approach | Valid |
| 3E0R3SF | Introduction of Other Gas into Spinal Canal, Percutaneous Approach | Valid |
| 3E0R3TZ | Introduction of Destructive Agent into Spinal Canal, Percutaneous Approach | Valid |
| 3E0R7SF | Introduction of Other Gas into Spinal Canal, Via Natural or Artificial Opening | Valid |
| 3E0S302 | Introduction of High-dose Interleukin-2 into Epidural Space, Percutaneous Approach | Valid |
| 3E0S303 | Introduction of Low-dose Interleukin-2 into Epidural Space, Percutaneous Approach | Valid |
| 3E0S304 | Introduction of Liquid Brachytherapy Radioisotope into Epidural Space, Percutaneous Approach | Valid |
| 3E0S305 | Introduction of Other Antineoplastic into Epidural Space, Percutaneous Approach | Valid |
| 3E0S30M | Introduction of Antineoplastic, Monoclonal Antibody, into Epidural Space, Percutaneous Approach | Valid |
| 3E0S328 | Introduction of Oxazolidinones into Epidural Space, Percutaneous Approach | Valid |
| 3E0S329 | Introduction of Other Anti-infective into Epidural Space, Percutaneous Approach | Valid |
| 3E0S33Z | Introduction of Anti-inflammatory into Epidural Space, Percutaneous Approach | Valid |
| 3E0S36Z | Introduction of Nutritional Substance into Epidural Space, Percutaneous Approach | Valid |
| 3E0S37Z | Introduction of Electrolytic and Water Balance Substance into Epidural Space, Percutaneous Approach | Valid |
| 3E0S3BZ | Introduction of Anesthetic Agent into Epidural Space, Percutaneous Approach | Valid |
| 3E0S3CZ | Introduction of Regional Anesthetic into Epidural Space, Percutaneous Approach through FY2017 | Retired |
| 3E0S3GC | Introduction of Other Therapeutic Substance into Epidural Space, Percutaneous Approach | Valid |
| 3E0S3HZ | Introduction of Radioactive Substance into Epidural Space, Percutaneous Approach | Valid |
| 3E0S3KZ | Introduction of Other Diagnostic Substance into Epidural Space, Percutaneous Approach | Valid |
| 3E0S3NZ | Introduction of Analgesics, Hypnotics, Sedatives into Epidural Space, Percutaneous Approach | Valid |
| 3E0S3SF | Introduction of Other Gas into Epidural Space, Percutaneous Approach | Valid |
| 3E0S3TZ | Introduction of Destructive Agent into Epidural Space, Percutaneous Approach | Valid |
| 3E0S7SF | Introduction of Other Gas into Epidural Space, Via Natural or Artificial Opening | Valid |
| 3E0T33Z | Introduction of Anti-inflammatory into Peripheral Nerves and Plexi, Percutaneous Approach | Valid |
| 3E0T3BZ | Introduction of Anesthetic Agent into Peripheral Nerves and Plexi, Percutaneous Approach | Valid |
| 3E0T3CZ | Introduction of Regional Anesthetic into Peripheral Nerves and Plexi, Percutaneous Approach through FY2017 | Retired |
| 3E0T3GC | Introduction of Other Therapeutic Substance into Peripheral Nerves and Plexi, Percutaneous Approach | Valid |
| 3E0T3TZ | Introduction of Destructive Agent into Peripheral Nerves and Plexi, Percutaneous Approach | Valid |
| 3E0U028 | Introduction of Oxazolidinones into Joints, Open Approach | Valid |
| 3E0U029 | Introduction of Other Anti-infective into Joints, Open Approach | Valid |
| 3E0U0GB | Introduction of Recombinant Bone Morphogenetic Protein into Joints, Open Approach | Valid |
| 3E0U0GC | Introduction of Other Therapeutic Substance into Joints, Open Approach | Valid |
| 3E0U304 | Introduction of Liquid Brachytherapy Radioisotope into Joints, Percutaneous Approach | Valid |
| 3E0U305 | Introduction of Other Antineoplastic into Joints, Percutaneous Approach | Valid |
| 3E0U30M | Introduction of Antineoplastic, Monoclonal Antibody, into Joints, Percutaneous Approach | Valid |
| 3E0U328 | Introduction of Oxazolidinones into Joints, Percutaneous Approach | Valid |
| 3E0U329 | Introduction of Other Anti-infective into Joints, Percutaneous Approach | Valid |
| 3E0U33Z | Introduction of Anti-inflammatory into Joints, Percutaneous Approach | Valid |
| 3E0U36Z | Introduction of Nutritional Substance into Joints, Percutaneous Approach | Valid |
| 3E0U37Z | Introduction of Electrolytic and Water Balance Substance into Joints, Percutaneous Approach | Valid |
| 3E0U3BZ | Introduction of Anesthetic Agent into Joints, Percutaneous Approach | Valid |
| 3E0U3GB | Introduction of Recombinant Bone Morphogenetic Protein into Joints, Percutaneous Approach | Valid |
| 3E0U3GC | Introduction of Other Therapeutic Substance into Joints, Percutaneous Approach | Valid |
| 3E0U3HZ | Introduction of Radioactive Substance into Joints, Percutaneous Approach | Valid |
| 3E0U3KZ | Introduction of Other Diagnostic Substance into Joints, Percutaneous Approach | Valid |
| 3E0U3NZ | Introduction of Analgesics, Hypnotics, Sedatives into Joints, Percutaneous Approach | Valid |
| 3E0U3SF | Introduction of Other Gas into Joints, Percutaneous Approach | Valid |
| 3E0U3TZ | Introduction of Destructive Agent into Joints, Percutaneous Approach | Valid |
| 3E0U4GC | Introduction of Other Therapeutic Substance into Joints, Percutaneous Endoscopic Approach | Valid |
| 3E0V0GB | Introduction of Recombinant Bone Morphogenetic Protein into Bones, Open Approach | Valid |
| 3E0V0GC | Introduction of Other Therapeutic Substance into Bones, Open Approach | Valid |
| 3E0V305 | Introduction of Other Antineoplastic into Bones, Percutaneous Approach | Valid |
| 3E0V30M | Introduction of Antineoplastic, Monoclonal Antibody, into Bones, Percutaneous Approach | Valid |
| 3E0V328 | Introduction of Oxazolidinones into Bones, Percutaneous Approach | Valid |
| 3E0V329 | Introduction of Other Anti-infective into Bones, Percutaneous Approach | Valid |
| 3E0V33Z | Introduction of Anti-inflammatory into Bones, Percutaneous Approach | Valid |
| 3E0V36Z | Introduction of Nutritional Substance into Bones, Percutaneous Approach | Valid |
| 3E0V37Z | Introduction of Electrolytic and Water Balance Substance into Bones, Percutaneous Approach | Valid |
| 3E0V3BZ | Introduction of Anesthetic Agent into Bones, Percutaneous Approach | Valid |
| 3E0V3GB | Introduction of Recombinant Bone Morphogenetic Protein into Bones, Percutaneous Approach | Valid |
| 3E0V3GC | Introduction of Other Therapeutic Substance into Bones, Percutaneous Approach | Valid |
| 3E0V3HZ | Introduction of Radioactive Substance into Bones, Percutaneous Approach | Valid |
| 3E0V3KZ | Introduction of Other Diagnostic Substance into Bones, Percutaneous Approach | Valid |
| 3E0V3NZ | Introduction of Analgesics, Hypnotics, Sedatives into Bones, Percutaneous Approach | Valid |
| 3E0V3TZ | Introduction of Destructive Agent into Bones, Percutaneous Approach | Valid |
| 3E0V4GC | Introduction of Other Therapeutic Substance into Bones, Percutaneous Endoscopic Approach | Valid |
| 3E0W305 | Introduction of Other Antineoplastic into Lymphatics, Percutaneous Approach | Valid |
| 3E0W30M | Introduction of Antineoplastic, Monoclonal Antibody, into Lymphatics, Percutaneous Approach | Valid |
| 3E0W328 | Introduction of Oxazolidinones into Lymphatics, Percutaneous Approach | Valid |
| 3E0W329 | Introduction of Other Anti-infective into Lymphatics, Percutaneous Approach | Valid |